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ABSTRACT
As one of the most abundant constituents of the tumour microenvironment (TME), cancer-
associated fibroblasts (CAF) display critical roles during tumour progression and metastasis.
Multiple classes of molecules including growth factors, cytokines, proteases and extracellular
matrix proteins, are produced by CAF to act as mediators of the stroma-tumour interactions. One
of the main channels for this communication is associated with extracellular vesicles (EV), which
are secreted particles loaded with protein and genetic information. In this study, we evaluated
the effects of EV derived from CAF primary human cell lines (n = 5) on proliferation, survival,
migration, and invasion of oral squamous cell carcinoma (OSCC) cells. As controls, EV from human
primary-established normal oral fibroblasts (NOF, n = 5) were used. Our in vitro assays showed
that CAF-EV significantly induces migration and invasion of OSCC cells and promote
a disseminated pattern of HSC-3 cell invasion in the 3D organotypic assay. Furthermore, gene
expression analysis of EV-treated cancer cells revealed changes in the pathways associated with
tumour metabolism and up-regulation of tumour invasion genes. Our findings suggest
a significant role of CAF-EV in promoting the migration and invasion of OSCC cells, which are
related to the activation of cancer-related pathways.
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Oral squamous cell carcinoma (OSCC) is the sixth
most common cancer worldwide and represents more
than 90% of all malignancies of the head and neck,
affecting mostly the floor of mouth and tongue [1]. As
a solid tumour, the cooperation between cancer cells
and tumour microenvironment (TME) is essential for
OSCC progression, in which the so-called cancer-
associated fibroblasts (CAF) play a major role [2].
CAF is the most abundant cell type within the TME
and are recognized as fibroblast-like cells that acquire
the ability to express isoform α of the smooth muscle
actin (α-SMA) [3]. These cells originate either from
resident fibroblasts, mesenchymal stem cells recruited
from bone marrow or cancer cells that have undergone
an epithelial-mesenchymal transition (EMT) [4]. In
OSCC, CAF has been shown to promote tumour cell
migration and invasion [5], proliferation [6], adhesion
[7], immunosuppression [8], angiogenesis [9], and
worsen the patients’ prognosis [10].
A major mode of communication between tumour
cells and TME components is through the secretion of
extracellular vesicles (EV) [11]. EV is a heterogeneous
group of particles composed of a lipid bilayer and
loaded with transmembrane and cytosolic proteins, as
well as DNA and different types of RNA [12]. EV, as an
umbrella term, covers vesicles that vary in size (from 30
to 2000 nm in diameter) and intracellular origin or
biogenesis, which are generally reported as exosomes
or microvesicles [13]. Exosomes are thought to be
around 30–150 nm in diameter and are formed by
inward budding of endosomal membranes. In turn,
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microvesicles are larger vesicles ranging from 100 to
1000 nm in diameter, ubiquitously assembled at and
released from the plasma membrane through outward
protrusion or budding [14].
EV may carry a common set of components
involved in their biogenesis and structure, but also
several factors to interact with target cells [15]. It is
known that cancer-derived EV exert complex cross-
talk effects on neighbouring stroma cells, contributing
to the formation of pre-metastatic niches, promoting
angiogenesis, modulating tumour stroma and inter-
fering with the immune response [16]. Furthermore,
EV derived from TME cells may also modulate reci-
pient cells, contributing to the formation of a highly
complex stroma able to modulate the invasive and
metastatic potential of the cancer cells [16].
Together, EV secreted by both tumour and TME
cells may instigate a functional pathway, favouring
cancer progression [17]. In this study, we show that
CAF-EV interacts with OSCC cells and are able to
stimulate their invasive potential.
Material and methods
Cell culture
Five primary cell cultures of both CAF and normal fibro-
blasts (NOF) were established, respectively, from OSCC
and healthy human oral mucosa. CAF was isolated from
histologically well-differentiated OSCC, removed from
the floor of the mouth or the lateral border of the tongue.
Fragments from both normal and cancerous tissues were
washed three times in Dulbecco’s modified Eagle’s media
(DMEM, Invitrogen, CA, USA) with antibiotics (1:200)
and Mycozap™ 2 µl/ml (Lonza, Basel, Swiss), immediately
after removal. With the aid of sterilized tweezers and
scalpel, tissue fragments were cut in smaller pieces and
incubated in DMEM supplemented with 10% fetal bovine
serum (FBS, Invitrogen, CA, USA) and antibiotics. The
media was exchanged every week until cells detached and
became confluent. Both cell types were cultured up to the
seventh passage maximum.
Four commercial human tongue OSCC cell lines,
representing different levels of aggressiveness, were
used in this study, as follows: HSC-3 and SAS (Health
Science Research Resources Bank, Osaka, Japan), show-
ing higher invasive and metastatic potential, and the
less aggressive SCC-15 and SCC-25 cell lines (ATCC,
VA, USA). OSCC cells were cultured in 1:1 DMEM/
F-12 containing 10% FBS (Invitrogen, CA, USA), anti-
biotics and 0.4 ng/ml hydrocortisone (all from Sigma-
Aldrich, Missouri, USA). All cell lines were grown in
a humidified atmosphere of 5% CO2 at 37ºC. This
study was approved by the Human Research Ethics
Committee from the School of Dentistry, University
of Campinas, Brazil.
Quantitative PCR (qRT-PCR)
Total RNA was isolated with TRIzol® reagent and quan-
titative reverse transcription-PCR (qRT-PCR) was per-
formed with the StepOne Plus instrument (Applied
Biosystems, CA, USA) as previously described [3].
Individual samples were normalized according to the
levels of the housekeeping PPIA (Peptidylprolyl
Isomerase A) and efficiency curves were created through
serial cDNA dilutions. The primer sequences used in this
study are described in Supplementary Table 1.
Western blot
Western blot analysis was performed as described before
[5], using anti-α-SMA (monoclonal anti-human, clone
1A4, Dako, 1:400) and anti-β-actin (clone AC15, Sigma-
Aldrich,1:30,000) as primary antibodies, and a fluorescent
anti-mouse (APC/Cy7-conjugated antibody, Abcam,
1:1000) as the secondary antibody. The protein sign was
detected using the UVITEC chamber (Cambridge, UK)
under infrared light, and the relative expression was cal-
culated using the Image J v1.46o software (National
Institute of Health, Bethesda, Maryland, USA).
Immunofluorescence
Then, 1000 NOF and CAF were plated with 500 µl of
complete medium in each well of an 8-wells culture
chamber slide (Lab Tek, Nunc, Naperville, IL, USA) and
incubated for 24 h. After washing with 150 µl of 1 × PBS,
cells were fixed in 70% ethanol for 30 min and washed
again three times with 500 µl of 1 × PBS. Cells were then
incubated for 1 h with mouse anti-α-SMA antibody
(monoclonal anti-human, clone 1A4, Dako, 1:100), fol-
lowed by incubation with goat anti-mouse IgG conju-
gated with fluorescein (Vector Labs, Burlingame,
CA, USA) at 1:250. Cells were mounted with
Vectashield containing DAPI (Vector Labs, Burlingame,
CA, USA) and examined under a photomicroscope
equipped with epifluorescence (DMR Microscope, Leica,
Germany). To generate fluorescent labelled images, cells
were excited at 480/40 nm with a 527/30 bandpass filter.
Senescence assay
The Senescence Detection Kit® (Abcam, Cambridge,
UK) was used to measure the percentage of senescent
cells among CAF and NOF cultures through the
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expression of β-galactosidase activity, following the
manufacturer’s instructions.
EV isolation, quantification, and characterization
EV was isolated using a differential ultracentrifugation
method with some modifications [18]. After culturing
cells under serum-free conditions for 48 h, the conditioned
medium (CM) was collected and centrifuged as following:
200 g for 10 min, 10.000 g for 90 min, and 100.000 g for
90 min, all at +4ºC. After air drying, EV were recovered in
100 µl of filtered PBS and stored at −80ºC. EV protein
quantification was obtained using the colorimetric DC
Protein Assay (BioRad®, CA, USA) following the manu-
facturer’s instructions. Nanoparticle Tracking Analysis
(NTA – NanoSight NS300, Wiltshire, UK) was used to
check the size distribution and the concentration of the
vesicles, and immunoelectron microscopy (ImmunoEM)
was applied using a gold-conjugated antibody against
CD63 (1:50, BD Pharmingen, CA, USA), both as pre-
viously described [19]. The Exo-Check™ exosome antibody
array (System Biosciences, CA, USA) was also used to
characterize the EV preparations, following the manufac-
turer’s recommendations. The relative expression of each
protein was calculated using the Image J v1.46o software
(National Institute of Health, USA).
EV treatment of human OSCC cell lines
To assess the effects of EV on malignant phenotypes,
oral cancer cells were cultured in serum-free media
containing 0.05 µg EV/103 cells. Initially, tumour cells
were treated with EV from each one of the five NOF or
CAF lines, and afterward with a pool of vesicles. To
prepare pooled EV, equal amounts of vesicles from
each of the five NOF or CAF lines were merged. The
same total concentration (0.05 µg pooled EV/103 cells)
was applied to each assay. Cancer cells were also cul-
tured in the absence of EV (negative control), in order
to be compared with the test groups.
Invasion and horizontal migration assays
Transwell inserts (Corning, New York, USA) were used
in 24-well plates to assess the individual effect of each
NOF- and CAF-EV in the cancer cell invasion (HSC-3,
SAS, SCC-15, SCC-25) through myogel solidified with
low-melting agarose [20]. Cells were plated on top of the
inserts together with EV in serum-free medium, either
individually or pooled into two groups (CAF vs. NOF).
After 72 h of incubation, the invasive cells were measured
[21]. The 3D-myoma organotypicmodel [22] was applied
with the HSC-3 cells co-cultured with pooled NOF or
CAF derived EV. HSC-3 cells were seeded together with
pooled NOF-EV and CAF-EV on the discs and allowed to
invade into the myomas for 14 days. After that, the
myomas were fixed in 4% formalin solution and immu-
nostained with the pan-cytokeratin antibody (monoclo-
nal mouse anti-human cytokeratin, AE1/AE3–M3515,
dilution 1:200, Dako, CA, USA). Pictures were taken
from the slides and analyzed on Image J v1.46o
(National Institute of Health, USA).
Scratch wound healing assay was used to assess the
effect of pooled NOF- and CAF-EV in HSC-3 cell
migration, using the Zeiss Cell Observer spinning disc
confocal (ZEISS, Ostalbkreis, Germany). Starved cells
were seeded in a 24-well plate together with pooled
NOF- and CAF-EV and proceed as explained
before [20].
Proliferation and apoptosis analyses
The bromodeoxyuridine-labelling assay (Cell
Proliferation ELISA BrdU assays, Roche, Mannheim,
Germany) was used to evaluate HSC-3 cell prolifera-
tion, whereas cell death was assessed by annexin
V-labelling assay [21] upon EV treatment. Cells were
incubated with pooled NOF- or CAF-EV and prolifera-
tion and apoptosis were determined 24 h later. The
annexin-V labelling assay was also used to determine
the apoptosis rate of NOF and CAF cell lines after
serum deprivation during EV isolation procedures.
To confirm the apoptosis results on HSC-3 treated
cells, ruling out the possibility of a false positive result
based on the transfer of phosphatidylserine from EV to
cells, a TUNEL assay (Roche, Mannheim, Germany)
was performed following the manufacturer’s instruc-
tions. As positive control of the reaction, cells were
treated with 0.03 μM staurosporine (Invitrogen, CA,
USA) as previously described [21].
EV proteomics
EV (3 × 108) from CAF and NOF were suspended in
up to 30 µl of urea buffer (50 mM Tris-HCl pH 7.5,
8 M urea, 2 M thiourea, and 1 mM DTT) for protein
extraction. The content of EV proteins was analyzed
by mass spectrometry. Briefly, samples in urea buffer
were sonicated for 5 min at RT. The protein extracts
were reduced, alkylated, trypsin digested and desalted
as previously described [23]. Tryptic-digested peptides
were dried in a speed-vac instrument and identified in
an ETD enabled LTQ Orbitrap Velos mass spectro-
meter (Thermo Fisher Scientific, Bremen, Germany)
connected to the EASY-nLC system (Proxeon
Biosystem, Florida, USA) through a Proxeon
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nanoelectrospray ion source in a data-dependent
mode. Peptides were separated by a 2–30% acetoni-
trile gradient in 0.1% formic acid using an analytical
PicoFrit Column (20 cm × ID75 μm, 5 μm particle
size, New objective) at a flow rate of 300 nl/min over
220 min. The nanoelectrospray voltage was set to
2.2 kV, and the source temperature was 275°C. All
instrument methods for the LTQ Orbitrap Velos were
run in the data-dependent analysis (DDA) mode. The
full scan MS spectra (m/z 300–1.600) were acquired in
the Orbitrap analyzer after accumulation to a target
value of 1e6. The resolution in the Orbitrap was set to
r = 60.000. The 20 most intense peptide ions with
charge states of ≥2 were sequentially isolated to
a target value of 5.000 and fragmented in the linear
ion trap by low-energy CID (normalized collision
energy of 35%). The signal threshold for triggering
an MS/MS event was set to 1.000 counts. Dynamic
exclusion was enabled with an exclusion size list of
500, exclusion duration of 60 s, and a repeat count of
1. An activation q = 0.25 and activation time of
10 ms was used. Protein data were processed using
Proteome Discoverer 1.3 (Thermo Fisher Scientific,
CA, USA) following a published protocol [24].
Peptides were identified by using the Sequest search
engine, where target-decoy searches were performed
against the Homo Sapiens UniProt database
(HUMAN_Uniprot_release_07012015.fasta). The par-
ent and fragment mass tolerances were set at 10 ppm
and 0.5 Da, respectively. The enzyme used was tryp-
sin, and the maximum allowable cleavages were set to
2. FDR for the peptide and protein levels were both
set at 0.01.
Protein data analysis
The protein datasets generated by Proteome Discoverer
analysis were clustered in categories depending on their
known main biological function using two different open
source bioinformatics resources: DAVID Bioinformatics
Resource 6.82 and PANTHER (Protein Analysis Through
Evolutionary Relationships) database 3. In both cases, the
whole Homo sapiens genome was employed as
a background list. The analysis of cellular components
and biological processes was performed in DAVID and
selecting the GO terms for Cellular Component
(GOTERM_CC_FAT) and for Biological Process
(GOTERM_BP DIRECT). Pathway over-representation
analysis was performed using DAVID bioinformatics
resource and comparing the representation of the differ-
ent KEGG terms (KEGG_PATHWAY) to the expected
pathway representation in human. This analysis was
coupled with the pathway enrichment analysis performed
with PANTHER using the PANTHER Molecular
Function, Pathway keywords and exported as a bar
chart of representation percentages.
Microarray gene expression analysis of EV-treated
HSC-3 cells
HSC-3 cells were incubated with pooled NOF- or CAF-
EV (or without EV) in triplicates. After incubation,
cells were washed in PBS and total RNA was extracted
by Qiagen RNA kit, followed by DNAse digestion
(Qiagen, Hilden, Germany). Following manufacturer’s
instructions, biotinylated cDNA was synthesized and
fragmented to 35 to 200 nt (GeneChip 3ʹIVT Express
kit, Affymetrix, CA, USA) and hybridized to arrays
(Affymetrix GeneChip Human Genome U133 Plus
2.0 Arrays). The arrays were scanned on GeneChip
Scanner 3000, and the dChip software [25] was used
for expression analyses (GEO, GSE85435).
To generate the final list of interest, we selected the
genes with significantly differing expression (p < 0.05)
between NOF- and CAF-EV treatment presenting fold
changes ≥1.3 (for up-regulation) or ≤1.3 (for down-
regulation), which were normalized by the control. The
list was imported into the Enrichr system (http://amp.
pharm.mssm.edu/Enrichr/) [26] to analyze the main
enriched pathways (KEGG 2016) and transcription
factors (ChEA 2016), using the Homo sapiens genome
as background. The criteria for selecting the top terms
were: (1) lowest p-value (up to ≤0.05), (2) minimum of
two genes assigned in the cluster, and (3) exclusion of
pathways annotated for viral conditions or diseases not
associated with cancer.
Statistical analysis
Mann-Whitney U test or one-way analysis of variance
(ANOVA) with post hoc comparisons based on the
Tukey’s multiple comparisons test were applied using
the GraphPad Prism 5 software. The level of signifi-
cance considered was 5% (p ≤ 0.05).
Results
Characterization of CAF cell lines
Cells were tested for the expression of α-SMA, the most
reliable marker for CAF. As expected, CAF cells
showed higher amounts of this marker in both western
blot (Figure 1(a)) and qPCR (Figure 1(b)). To confirm,
immunofluorescence staining showed that CAF cells
presented the typically stressed actin fibres more evi-
dent than NOF (Figure 1(c)). Among the other
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putative markers tested by qPCR, only TIMP-1 showed
higher expression in CAF compared to NOF cells. The
complete panel of the tested markers is presented in
Supplementary Figure 1. The senescence level, repre-
sented by the β-galactosidase activity, was similar
among all cell lines, showing an average activity vary-
ing from 12% to 21% (Figure 1(d)).
Characterization of EV
NOF and CAF cells were tested after 48 h of serum
deprivation for EV isolation and showed no increase of
apoptosis when comparing to cells cultured in complete
medium (Supplementary Figure 2(a)). The size distribu-
tion of the isolated EV was similar in NOF- and CAF-
EV, most of them being around 100 and 200 nm
(Supplementary Figure 2(b)). The concentration of EV,
as measured by EV/ml of CM, varied among cell lines
but CAF4 and CAF5 were the most productive
(Supplementary Figure 2(c)). The samples were enriched
in some EV markers, such as CD81, TSG101, FLOT1,
and ALIX, showing similar expression in both groups
(Supplementary Figure 2(d,e)). Some of the vesicles were
positively labelled with the anti-CD63 antibody in the
ImmunoEM and were seen as round- or cup-shaped
bilayer structures with varied size, which were mostly
distributed as isolated rather than aggregated particles
(Supplementary Figure 2(f)).
Effects of CAF-EV on OSCC invasion
EV from each NOF and CAF cell line was cultured
with OSCC cells and let to invade into a myogel matrix.
The CAF-EV were individually able to induce invasion
of the OSCC cell lines, with more intense effects in the
aggressive cell lines: HSC-3 when compared to control
Figure 1. Characterization of the primary NOF and CAF cell cultures. The relative expression of α-SMA was higher in CAF when compared
to NOF cells, as revealed by both western blot (a), which can be graphically visualized by the densitometry analysis relative to β-actin
expression, and by qRT-PCR (b). (c) Representative images of CAF and NOF immunofluorescence assay revealed the stressed actin fibres
typical of CAF. (d) The senescence of these cells was accessed by the expression of β-galactosidase activity, and the bars represent the
percentage of positive cells. The senescence rate was of approximately 20% maximum for all cell cultures.
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(p = 0.006) and to NOF-EV (p = 0.01); and SAS for the
comparison with control (p = 0.007) (Figure 2(a)).
A lower effect was found in the less aggressive cell
line SCC-15 when compared to control (p = 0.047)
and to NOF-EV (p = 0.048). The invasion of SCC-25
was not significantly different for any comparisons
between treatments or control (Figure 2(a)). Still,
when the vesicles were pooled into NOF or CAF
group, the invasion was significantly induced by the
pooled CAF-EV in HSC-3 cells comparing to control
(p = 0.01) and to NOF-EV (p = 0.001; Figure 2(b,c)).
Since HSC-3 cells were the most responsive to pooled
EV, the subsequent analyses were performed on this cell
line. Figure 3(a) illustrates the assessment of the invasive
potential of the HSC-3 cells in the 3D-myoma organoty-
pic model. The HSC-3 cells cultured with pooled CAF-
EV invaded in a broader area when compared to the
control without EV (p = 0.039, Figure 3(b) left); deeper
when compared to NOF-EV (p = 0.003) and to the
negative control (p < 0.0001) (Figure 3(b) middle); and
showing smaller tumor islands when compared to the
NOF-EV group (p = 0.005) and to the negative control
(p = 0.047) (Figure 3(b) right).
Effects of CAF-EV on HSC-3 cell migration,
proliferation, and apoptosis
Migration, proliferation, and apoptosis were evaluated
in HSC-3 cells incubated with pooled EV. On the
horizontal cell migration assay, HSC-3 cells cultured
with CAF-EV closed the wounds faster than NOF-EV
at 12 and 24 h (p < 0.05; Figure 4(a)). The treatment
did not impair the proliferation of tumour cells (Figure
4(b)). The apoptosis rate was significantly higher in
CAF-EV group when compared to the control in the
annexin-V assay (p < 0.05; Figure 4(c)), as well as in
the TUNEL assay (p < 0.05; Figure 4(d)).
Protein content analysis from oral NOF- and CAF-EV
To determine the protein content profile of CAF and
NOF-EV, we performed a mass spectrometry-based pro-
teomic discovery analysis approach and analyzed three
independent experiments. A total of 77 and 141 proteins
were detected, respectively, in CAF-EV and NOF-EV, of
which 50 proteins were common between both vesicle
population (~35% overlap), most likely representing
constitutive fibroblast secreted EV (Figure 5(a)). The
set of proteins exclusively identified in CAF-EV (27
proteins) or NOF-EVs (64 proteins), along with com-
mon proteins, including the up-or down-regulates pro-
Figure 2. CAF-EV induce invasion of OSCC cells. (a) CAF-EV from
each of the five cell lines were individually able to induce sig-
nificantly the invasion of the tumour cells (HSC-3, SAS, SCC-15) in
the myogel-coated transwell when compared to NOF-EV and to
the control without vesicles. (b) Representative images of the
invaded HSC-3 cells. (c) Pooled CAF-EV were also able to induce
a higher invasion rate of HSC-3 cells. *p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001.
Figure 3. CAF-EV promote a budding pattern of invasion. Pooled NOF- or CAF-EV were cultured with HSC-3 cells and let to invade within
the 3D-myoma organotypic model for 14 days. (a) Representative images of the invaded cells stained with pan-cytokeratin (scale bars
represent 400 µm). (b) Quantification of the invaded cells. CAF-EV induced HSC-3 cells to invade deeper and in smaller tumour cell islands
compared to the NOF-EV treated and to the control cells (HSC-3 cells without EV). *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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teins considering a fold-change cut off ≥2, are shown in
Supplementary Table 2. Among the identified proteins
in our dataset, some are listed amidst the top EV
markers in EVpedia database (www.evpedia.info/),
such as Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), Pyruvate kinase (PKM), Heat shock cognate
Figure 4. Effect of CAF-EV on migration, proliferation, and apoptosis of HSC-3 cells. (a) Pooled NOF-and CAF-EV were added to the
scratched wounds of HSC-3 cells. HSC-3 cells migrated faster when cultured with CAF-EV at 6 h, 12 h and 24 h (p < 0.05) compared
to NOF-EV. Pictures represent the initial (0 h) and final (24 h) views of the wounded areas, delimitated by a white line. The graph on
the left panel shows the decrease of wound area in percentages when the area at 0 h was set to be 100%. The EV treatment did not
affect the proliferation at 24 h (b), but the apoptosis rate at 24 h was significantly higher in HSC-3 cells treated with CAF-EV
compared to the control (c), showed as a percentage of apoptotic cells, as resulted from an annexin-V based apoptosis assay. (d) To
confirm the results, a TUNEL assay was also performed in EV-treated HSC-3 cells, resulting in similar findings. *p ≤ 0.05.
Figure 5. Proteome of constitutive EV released from Fibroblasts. (a) Venn diagram of the numerical values for common and
unique proteins present in CAF (violet) and NOF (grey). (b) Analysis of cellular component GO terms. The proteins detected in both
CAF and NOF fractions (total 50 constitutive EV proteins) were grouped using GO terms related to cellular component analysis
process using DAVID [56]. (c) Analysis of molecular function GO terms of total EV proteins of both groups. (d, e) EV proteins were
grouped in CAF (D) or NOF (E) using (GO) terms related to biological process analysis using DAVID (p < 0.05) and shown in
Supplementary Table 7. The graph shows the percentage of proteins identified by mass spectrometry that fall into designated GO
category relative to the total number of proteins in the category. GO FAT was used to minimize the redundancy of general GO terms
in the analysis. Categories with enrichment greater than 6% are shown.
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71 kDa protein (HSPA8), L-lactate dehydrogenase
A chain and B chain (LDHA, LDHB), and Annexin 2
and 5 (ANXA2, ANXA5). The recognition of common
EV markers can improve the current methods of identi-
fication and characterization of these vesicles. It is
worthy to mention that the current EV databases do
not present a protein dataset originated specifically from
oral NOF or CAF. After screening the three fibroblast-
derived EV protein dataset available in EVpedia for
Homo sapiens (accessed on 15 August 2018), it was
found that 45 proteins described in this study have not
been identified before in fibroblasts (either normal or
CAF). The list was manually reviewed and is detailed in
the Supplementary Table 3.
Analysis of GO terms showed that the cellular com-
ponent terms “extracellular region”, “membrane-
bounded vesicle”, “extracellular organelle”, “extracellular
vesicle”, and “extracellular exosome” were the highest
enriched fractions (above 68%) of constitutive EVs
(CAF and NOF in total) (Supplementary Table 4,
Figure 5(b)), which are consistent with the vesicular
and extracellular nature of these EV proteins. As for
the terms “endosome”, “endolysosome”, “lysosomal
membrane” and “lytic vacuole membrane” were the
major exclusively enriched in CAF-EV (Supplementary
Table 5), while “cell junction”, “adherens and anchoring
junction”, “cytosol”, “cell-substrate junction” and “focal
adhesion” were among the major exclusive terms in
NOF-EV(Supplementary Table 6). The GO analysis of
molecular functions showed that protein binding is the
major category for both NOF and CAF, although in
significantly different proportions (25% enrichment for
NOF, and approximately 7.5% for CAF). In line, iden-
tical protein binding, serine-type endopeptidase activity,
signalling receptor and protein kinase binding were the
most enriched for the CAF-EV proteins set, while RNA
binding, ATP binding, calcium ion, protein domain
specific, metal ion, integrin and identical protein bind-
ing, were the top enriched for the NOF-EV proteins
(Figure 5(c)). DAVID analysis of biological processes
revealed GO terms related to response to negative reg-
ulation of endopeptidase activity, receptor-mediated
endocytosis, platelet degranulation, and collagen cata-
bolic process as significantly predominant categories
(each one representing 12% of all processes verified,
p < 0.05) in CAF-EV protein content (Supplementary
Table 7, Figure 5(d)). In the other hand, NOF-EV pro-
tein content analyzed revealed the top enriched terms
related to negative regulation of apoptotic process
(14.5%) and cell adhesion (12.9%) (Supplementary
Table 7, Figure 5(e)).
CAF-EV modulates gene expression of HSC-3
malignant cell line
In order to determine whether the EV content has
a modulatory effect on tumour cells, cDNA micro-
array was applied on total RNA isolated from HSC-3
cells treated with NOF- or CAF-EV. A total of 32
genes were significantly differentially expressed
(FC ≥ 1.3), demonstrating the EV modulation of
gene expression pattern in the malignant oral cell
line. From these, 29 were up-regulated and 3 were
down-regulated in HSC-3 cells after CAF-EV treat-
ment (Supplementary Table 8). One of the negatively
regulated genes by CAF-EV was the Cell Division
Cycle 27 gene (CACD27), which is relevant for the
cell cycle progression controlling. The KEGG path-
ways enrichment analysis was applied to this group
of genes and the most significantly annotated were:
Proteoglycans in cancer, Metabolic pathways,
Leukocyte transendothelial migration, and
Regulation of actin cytoskeleton. All genes clustered
into these enriched pathways were up-regulated in
CAF-EV treatment group (Supplementary Table 9).
In an attempt to better understand the modulation
of gene expression by CAF-EV, we searched for tran-
scription factors associated with the listed genes using
Enrichr system [26] (Supplementary Table 10). To
narrow down the possibilities, the String tool (https://
string-db.org/) [27] was used to detect interactions
between these transcription factors and the CAF-EV
proteins. It was found that the SMAD Family Member
3 (SMAD3) can regulate the expression of seven of the
CAF-EV modulated genes (POLR2J4, POLD4,
BCL2L11, GPC1, GBA, FLOT1, FAM129B), and also
interacts with 3 CAF-EV proteins: Importin subunit
beta-1 (KPNB1), Thrombospondin-1 (THBS1), and
Interstitial collagenase (MMP1).
Discussion
The molecular mechanisms associated with CAF-
promoting tumorigenesis are only partially understood,
hampering the development of stromal-directed thera-
pies. Therapies targeting functional proteins expressed
by CAF, depletion of CAF by apoptosis and repro-
gramming CAF into normal fibroblasts are the current
strategies in testing, but the results so far are limited
[28]. Here we identified that EV released by CAF are
key promoters of OSCC migration and invasion via
activation of specific biological processes including
structural and motility pathways.
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CAF constitute the main component of TME and are
typically characterized by mesenchymal markers, such as
α-SMA [4]. Besides α-SMA, CAF expressed higher
mRNA amounts of TIMP-1, a member of the tissue
inhibitor of metalloproteinases family, when compared
with NOF. In consonance, upregulation of TIMP-1 was
shown to induce a transformation of normal liver fibro-
blasts into CAF [29] and to stimulate the accumulation of
CAF within prostate and colon cancer tissues [30]. It is
well accepted that CAF represents indeed
a heterogeneous cell population, and the expression of
different markers possibly reflect the cell of origin, the
activation state, and the tumour-promoting properties of
the cells [4]. Among the heterogeneous subtypes of CAF
in OSCC, the myofibroblastic and the senescent subtypes
are the most characterized ones. Both subtypes are α-
SMA-positive cells, characterized by tumour-promoting
roles, but senescent CAF show β-galactosidase activity
[31]. Once the CAF cell lines presented activity of the β-
galactosidase in under 20% of cells used in the present
study, a myofibroblastic pattern was observed in all cell
lines. To avoid the replicative senescence induction of
CAF, the cells in the experiments reported here were
cultured up to a maximum of seven passages.
CAF-EV induced OSCC cell invasion into a gelatinous
matrix and migration towards a wounded area, and the
strongest effect on invasion was seen in HSC-3, the most
aggressive cell line. In this case, CAF-EV may work by
boosting an innate characteristic of the cancer cells.
Similarly, Leca et al. [32] observed an increasedmigration
of pancreatic ductal adenocarcinoma cells after the
uptake of CAF-derived ANXA6 + EV, and Luga et al.
[33] showed that CAF exosomes stimulate breast cancer
cell migration and metastasis in a CD81-dependent man-
ner [32,33].
Tumour invasion was also tested into a solid
human leiomyoma tissue, and HSC-3 cells treated
with CAF-EV invaded deeper and as smaller budding
islands. High amounts of tumour budding have been
shown to significantly associate with lymph node
metastasis, depth of invasion, CAF-abundant stroma
in OSCC, and poor prognosis in oral tongue cancer
[34–36]. The budding formation is considered the
first step in the metastasis process of a solid tumour,
as the buds seem to be involved in degradation of the
peritumoral connective tissue, evasion of host
response and invasion into lymphatic and blood ves-
sels leading to local and distant metastasis [37,38].
Since our results demonstrated the correlation
between CAF-EV and tumour cells spreading in
a human leiomyoma matrix, it may represent the
initial step for local invasion and metastasis. The
treatment with CAF-EV did not alter the proliferation
of the cancer cells, which confirms a real invasive and
migratory phenotype. Interestingly, the budding phe-
nomenon could be related to the apoptotic phenotype
promoted by CAF-EV. As previously hypothesized by
Itoh et al. (2017), the CAF-led invasion is character-
ized by the movement of individual cancer cells away
from the tumour, and adequate cancer cell apoptosis
may promote cancer dissemination [39].
Protein cargo of CAF-EV has not been extensively
addressed before. It is important to recognize proteins
that are unique or differentially expressed in vesicles
derived from this cellular subtype, to better character-
ize them and understand the mechanisms underlying
their functional phenotypes. GO analysis of EV pro-
teins profile revealed that biological processes related
to cell adhesion and negative regulation of apoptosis
were the most frequent terms for NOF-EV. On con-
trary, CAF-EV seems to lose those properties since its
protein content was mainly related to collagen catabo-
lism and platelet degranulation. This proteolytic profile
can explain the migrative/invasive phenotype of cancer
cells when treated with CAF-EV. It has been shown
that increased adhesion to the extracellular matrix
(ECM) and decreased adhesion to tumour cells can
result in invasive tumour behaviours [40]. During the
initial process of tumour invasion, extracellular pro-
teases degrade the basement membrane, leading to
the migration of motile cancer cells through the basal
lamina stroma and subsequent remodelling of the
tumour stroma, where CAF play a pivotal role [41].
This remodelling results in structural and mechanical
changes in the stroma, promoting proangiogenic sig-
nalling and providing a safe niche for cancer cell sur-
vival and proliferation [42]. In addition, platelet
activation and degranulation have been shown to pro-
mote pro-survival and pro-angiogenic signalling in
ovarian cancer cells [43]. Platelets contribute to cancer
metastasis via facilitating tumour cell migration, inva-
sion, arrest within the vasculature, and even providing
protection from host-immune system defences [44].
Bioinformatic tools were applied to uncover the
genes differentially expressed in HSC-3 cells treated
with CAF- or NOF-EV, and most of them were
involved in metabolism pathways. It is hypothesized
that nutrient/oxygen deprived epithelial cancer cells
present within solid tumours are able to survive these
conditions as a result of their ability to undergo exten-
sive metabolic reprogramming, the so-called reverse
Warburg effect, and exploit the metabolic capacities
of stromal cells such as CAF [41]. In the other hand,
it was recently shown that EV can function as inde-
pendent, extracellular metabolic units able to modify
the concentrations of critical nutrients, with the
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potential to affect the physiology of their microenvir-
onment [45]. More specifically, CAF-EV can induce
central carbon metabolism in target cells and promote
tumour growth under nutrient deprivation or nutrient
stressed conditions, disabling tumour cells oxygen-
based energy production [46]. In line with our results,
Principe et al. (2018) suggested an enrichment of pro-
teins involved in metabolism and energy pathways in
CAF-EV when compared to normal fibroblasts [47].
Therefore, our study suggests a modulation of genes
involved in OSCC tumour metabolism, regulated by
the transfer of CAF-EV cargo.
Interestingly, Rho-associated coiled-coil kinase 2
(ROCK2) was clustered into three of the enriched path-
ways for CAF-EV modulated genes. ROCK2 is an
oncoprotein with important roles in tumour prolifera-
tion, apoptosis, adhesion, migration, and invasion, and
its deregulated expression has been reported in differ-
ent solid tumours [48]. Enhanced expression of
ROCK2 in an OSCC cell line was shown to increase
the activity of Rho GTPase signalling cascade, promot-
ing tumour cell migration and invasion [49]. We have
recently shown that in human OSCC samples, ROCK2
is highly expressed in 74% of the cases, its amount is
associated with advanced clinical stage, and its expres-
sion followed the increase of CAF density within the
stroma [48], which may suggest a crosstalk between
tumour and CAF cells. Together, these results suggest
that blocking tumour ROCK2 expression and/or its
modulation by CAF-EV could hamper OSCC invasion.
The top transcription factors associated with the CAF-
EVmodulated geneswere assessed, and SMAD3was found
to be one of the most representative molecules. SMAD3 is
the major intracellular mediator of TGF-β signalling, func-
tioning as both positive and negative regulator in carcino-
genesis [50]. It was recently reported that hepatocellular
carcinoma cells could promote cancer cell proliferation and
lung metastases formation in a paracrine/endocrinal way
through SMAD3-containing exosomes [51]. Since we did
not detect SMAD3 as an EV content, we speculated that
proteins inside the vesicles could interact with SMAD3 to
modulate the gene expression in cancer cells. Three pro-
teins overexpressed in CAF-EV from our dataset were
found to interact with SMAD3, being them Importin sub-
unit beta-1 (KPNB1), Thrombospondin-1 (THBS1), and
Interstitial collagenase (MMP1).
Among the genes from our dataset that can possibly
interact with SMAD3, some has been related to tumor-
igenesis. Glypican 1 (GPC1) is a surface proteoglycan
overexpressed in many cancer cells with the most
abundant increase observed in pancreatic cancer,
found to be specifically enriched on cancer cell-
derived exosomes [52]. In addition, GPC1 has been
suggested as an early diagnostic and prognostic marker
for pancreatic ductal adenocarcinoma [53]. The Bcl2-
Interacting Mediator of Cell Death (BCL2L11) belongs
to the BCL-2 family, and acts as a central regulator of
the intrinsic apoptotic cascade and mediates cell apop-
tosis [54]. The overexpression of this gene can justify
the apoptotic phenotype induced by CAF-EV in our
study. The Family With Sequence Similarity 129
Member B (FAM129B) is up-regulated in many types
of cancer, including breast, kidney, large intestine, and
lung, and was associated with tumour cell proliferation
and invasion [55]. Finally, Flotillin 1 (FLOT1) was
shown to be up-regulated in oral tongue cancer cell
lines and tumour tissue, and its overexpression was
correlated with shortened overall survival [56].
FLOT1 are lipid raft proteins that play important
roles in cell adhesion, actin cytoskeleton reorganiza-
tion, endocytosis, phagocytosis and the transduction
of cellular signals [56].
In summary, our results show that CAF-EV promotes
migration and budding pattern of invasion inOSCC cells.
The budding formation may represent the initial steps of
the local tumour invasion and could be related to the
further development of distant metastases. CAF-EV-
treated tumour cells revealed a modified gene expression
associated with metabolic pathways and up-regulation of
genes associated with tumour invasion such as ROCK2,
FLOT1, and FAM129B. These results suggest an active
transference of EV cargo from the surrounding stroma to
the tumour, and the detailed molecular mechanisms by
which this process develops needs to be further
investigated.
Acknowledgments
The skilful technical assistance of Ms Maija-Leena Lehtonen
(University of Oulu), Ph.D. Ilkka Miinalainen (Biocenter
Oulu Microscopy Service), Ph.D. Maija Risteli (University
of Oulu), Ph.D. Sami Yokoo (LNBio) and Ph.D. Fabio Teo
(Unicamp) is appreciated.
Disclosure of interest
The authors report no conflict of interest.
Disclosure statement
No potential conflict of interest was reported by the authors.
Funding
MRD was supported by grants from the Coordenação de
Aperfeiçoamento de Pessoal de Nivel Superior - CAPES,
Brasilia, Brazil [Finance Code 001] and Medical Research
10 M. R. DOURADO ET AL.
Center, University of Oulu, Finland. JK was supported by
a grant from the Finnish Cultural Foundation [Grant number
00130432]. RDC was supported by the Coordenação de
Aperfeiçoamento de Pessoal de Nivel Superior - CAPES,
Brasilia, Brazil [AUXPE-PVES-570/2013]. This study was sup-
ported by the grants from the Finnish Cancer Society, The
Sigrid Juselius Foundation, and the Conselho Nacional de
Desenvolvimento Científico e Tecnológico - CNPq, Brasíia,
Brazil [302964/2015-0].
ORCID
Mauricio Rocha Dourado http://orcid.org/0000-0002-
0906-4153
Ricardo D. Coletta http://orcid.org/0000-0001-5285-3046
References
[1] Warnakulasuriya S. Global epidemiology of oral and
oropharyngeal cancer. Oral Oncol. 2009;45
(4–5):309–316.
[2] Wu JS, Sheng SR, Liang XH, et al. The role of tumor
microenvironment in collective tumor cell invasion.
Future Oncol. 2017 May;13(11):991–1002.
[3] Sobral LM, Zecchin KG, Nascimento de Aquino S, et al.
Isolation and characterization of myofibroblast cell lines
from oral squamous cell carcinoma. Oncol Rep. 2011a
Apr;25(4):1013–1020.
[4] Prime SS, Cirillo N, Hassona Y, et al. Fibroblast activa-
tion and senescence in oral cancer. J Oral Pathol Med.
2017 Feb;46(2):82–88.
[5] Sobral LM, Bufalino A, Lopes MA, et al. Myofibroblasts
in the stroma of oral cancer promote tumorigenesis via
secretion of activin A. Oral Oncol. 2011b Sep;47
(9):840–846.
[6] Kellermann MG, Sobral LM, Da Silva SD, et al. Mutual
paracrine effects of oral squamous cell carcinoma cells
and normal oral fibroblasts: induction of fibroblast to
myofibroblast transdifferentiation and modulation of
tumor cell proliferation. Oral Oncol. 2008 May;44
(5):509–517.
[7] Cirillo N, Hassona Y, Celentano A, et al. Cancer-
associated fibroblasts regulate keratinocyte cell-cell adhe-
sion via TGF-β-dependent pathways in genotype-specific
oral cancer. Carcinogenesis. 2017 Jan;38(1):76–85.
[8] Takahashi H, Sakakura K, Kudo T, et al. Cancer-
associated fibroblasts promote an immunosuppressive
microenvironment through the induction and accumu-
lation of protumoral macrophages. Oncotarget. 2017 Jan
31;8(5):8633–8647.
[9] Kayamori K, Katsube K, Sakamoto K, et al. NOTCH3 is
induced in cancer-associated fibroblasts and promotes
angiogenesis in oral squamous cell carcinoma. PLoS
One. 2016 Apr 28;11(4):e0154112.
[10] Dourado MR, Guerra ENS, Salo T, et al. Prognostic
value of the immunohistochemical detection of
cancer-associated fibroblasts in oral cancer:
A systematic review and meta-analysis. J Oral Pathol
Med. 2018 May;47(5):443–453.
[11] Webber J, Yeung V, Clayton A. Extracellular vesicles as
modulators of the cancer microenvironment. Semin Cell
Dev Biol. 2015 Apr;40:27–34.
[12] Tkach M, Théry C. Communication by extracellular
vesicles: where we are and where we need to go. Cell.
2016 Mar 10;164(6):1226–1232.
[13] Verma M, Lam TK, Hebert E, et al. Extracellular vesi-
cles: potential applications in cancer diagnosis, prog-
nosis, and epidemiology. BMC Clin Pathol. 2015;15:6.
[14] Kalra H, Drummen GP, Mathivanan S. Focus on extra-
cellular vesicles: introducing the next small big thing.
Int J Mol Sci. 2016 Feb 6;17(2):170.
[15] Lo Cicero A, Stahl PD, Raposo G. Extracellular vesicles
shuffling intercellular messages: for good or for bad.
Curr Opin Cell Biol. 2015 Aug;35:69–77.
[16] Becker A, Thakur BK, Weiss JM, et al. Extracellular
vesicles in cancer: cell-to-cell mediators of metastasis.
Cancer Cell. 2016 Dec 12;30(6):836–848.
[17] Han L, Xu J, Xu Q, et al. Extracellular vesicles in the
tumor microenvironment: therapeutic resistance, clini-
cal biomarkers, and targeting strategies. Med Res Rev.
2017 Nov;37(6):1318–1349.
[18] Théry C, Amigorena S, Raposo G, et al. Isolation and
characterization of exosomes from cell culture super-
natants and biological fluids. Curr Protoc Cell Biol. 2006
Apr;Chapter 3: Unit 3.22. (3):3–22.
[19] Al-Samadi A, Awad SA, Tuomainen K, et al. Crosstalk
between tongue carcinoma cells, extracellular vesicles,
and immune cells in vitro and in vivo models.
Oncotarget. 2017 May 10;8(36):60123–60134.
[20] Salo T, Sutinen M, Hoque Apu E, et al. A novel human
leiomyoma tissue derived matrix for cell culture studies.
BMC Cancer. 2015 Dec;16(15):981.
[21] Bufalino A, Cervigne NK, de Oliveira CE, et al. Low
miR-143/miR-145 cluster levels induce activin
a overexpression in oral squamous cell carcinomas,
which contributes to poor prognosis. PLoS ONE.
2015;10(8):e0136599.
[22] Nurmenniemi S, Sinikumpu T, Alahuhta I, et al. A novel
organotypic model mimics the tumor microenvironment.
Am J Pathol. 2009 Sep;175(3):1281–1291.
[23] Winck FV, Prado Ribeiro AC, Ramos Domingues R,
et al. Insights into immune responses in oral cancer
through proteomic analysis of saliva and salivary extra-
cellular vesicles. Sci Rep. 2015 Nov;5(5):16305.
[24] Kawahara R, Meirelles GV, Heberle H, et al. Integrative
analysis to select cancer candidate biomarkers to targeted
validation. Oncotarget. 2015 Dec 22;6(41):43635–43652.
[25] Li C, Wong WH. Model-based analysis of oligonucleotide
arrays: expression index computation and outlier detection.
Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31–36.
[26] Kuleshov MV, Jones MR, Rouillard AD, et al. Enrichr:
a comprehensive gene set enrichment analysis web server
2016 update. Nucleic Acids Res. 2016 Jul 8;44(W1):W90–7.
[27] Szklarczyk D, Morris JH, Cook H, et al. The STRING
database in 2017: quality-controlled protein-protein
association networks, made broadly accessible. Nucleic
Acids Res. 2017;45:D362–68.
[28] Xu Y, Zhou X, Mei M, et al. Reprograming
carcinoma-associated fibroblasts by microRNAs. Curr
Mol Med. 2017;17(5):341–349.
JOURNAL OF EXTRACELLULAR VESICLES 11
[29] ZhengX,XuM,YaoB, et al. IL-6/STAT3 axis initiatedCAFs
via up-regulating TIMP-1 which was attenuated by acetyla-
tion of STAT3 induced by PCAF in HCC
microenvironment. Cell Signal. 2016 Sep;28(9):1314–1324.
[30] Gong Y, Scott E, Lu R, et al. TIMP-1 promotes accu-
mulation of cancer associated fibroblasts and cancer
progression. PLoS One. 2013 Oct 15;8(10):e77366.
[31] Kabir TD, Leigh RJ, Tasena H, et al. A miR-335/COX-2/
PTEN axis regulates the secretory phenotype of senes-
cent cancer-associated fibroblasts. Aging (Albany NY).
2016 Aug;8(8):1608–1635.
[32] Leca J, Martinez S, Lac S, et al. Cancer-associated
fibroblast-derived annexin A6+ extracellular vesicles
support pancreatic cancer aggressiveness. J Clin Invest.
2016 Nov 1;126(11):4140–4156.
[33] Luga V, Zhang L, Viloria-Petit AM, et al. Exosomes
mediate stromal mobilization of autocrine Wnt-PCP
signaling in breast cancer cell migration. Cell. 2012
Dec 21;151(7):1542–1556.
[34] Almangush A, Pirinen M, Heikkinen L, et al. Tumor
budding in oral squamous cell carcinoma: a
meta-analysis. Br J Cancer. 2018 Feb 20;118(4):577–586.
[35] Almangush A, Leivo I, Siponen M, et al. Evaluation of the
budding and depth of invasion (BD) model in oral tongue
cancer biopsies. Virchows Arch. 2018 Feb;472(2):231–236.
[36] Almangush A, Bello IO, Keski-Säntti H, et al. Depth of
invasion, tumor budding, and worst pattern of invasion:
prognostic indicators in early-stage oral tongue cancer.
Head Neck. 2014 Jun;36(6):811–818.
[37] Angadi PV, Patil PV, Hallikeri K, et al. Tumor budding
is an independent prognostic factor for prediction of
lymph node metastasis in oral squamous cell carcinoma.
Int J Surg Pathol. 2015 Apr;23(2):102–110.
[38] Seki M, Sano T, Yokoo S, et al. Tumor budding eval-
uated in biopsy specimens is a useful predictor of prog-
nosis in patients with cN0 early stage oral squamous cell
carcinoma. Histopathology. 2017 May;70(6):869–879.
[39] Itoh G, Chida S, Yanagihara K, et al. Cancer-associated
fibroblasts induce cancer cell apoptosis that regulates
invasion mode of tumours. Oncogene. 2017 Aug;36
(31):4434–4444.
[40] Yingzi L, Naveed H, Liang J, et al. Effects of mechanical
properties on tumor invasion: insights from a cellular
model. Conf Proc IEEE Eng Med Biol Soc.
2014;2014:6818–6821.
[41] Mitchell MI, Engelbrecht AM. Metabolic hijacking:
A survival strategy cancer cells exploit? Crit Rev Oncol
Hematol. 2017 Jan;109:1–8.
[42] Wang K, Wu F, Seo BR, et al. Breast cancer cells alter the
dynamics of stromal fibronectin-collagen interactions.
Matrix Biol. 2017;60–61:86–95.
[43] Egan K, Crowley D, Smyth P, et al. Platelet adhesion
and degranulation induce pro-survival and
pro-angiogenic signalling in ovarian cancer cells. PLoS
One. 2011;6(10):e26125.
[44] Serhan K, Gartung A, Panigrahy D. Drawing a link
between the thromboxane A(2) pathway and the role
of platelets and tumor cells in ovarian cancer.
Prostaglandins Other Lipid Mediat. 2018 Jul;137:40–45.
[45] Iraci N, Gaude E, Leonardi T, et al. Extracellular vesicles
are independent metabolic units with asparaginase
activity. Nat Chem Biol. 2017 Sep;13(9):951–955.
[46] Zhao H, Yang L, Baddour J, et al. Tumor microenvir-
onment derived exosomes pleiotropically modulate can-
cer cell metabolism. Elife. 2016 Feb;27(5):e10250.
[47] Principe S, Mejia-Guerrero S, Ignatchenko V, et al.
Proteomic analysis of cancer-associated fibroblasts
reveals a paracrine role for MFAP5 in human oral
tongue squamous cell carcinoma. J Proteome Res. 2018
Jun 1;17(6):2045–2059.
[48] Dourado MR, de Oliveira CE, Sawazaki-Calone I, et al.
Clinicopathologic significance of ROCK2 expression in
oral squamous cell carcinomas. J Oral Pathol Med. 2018
Feb;47(2):121–127.
[49] Jiang L, Liu X, Kolokythas A, et al. Downregulation of
the Rho GTPase signaling pathway is involved in the
microRNA-138-mediated inhibition of cell migration
and invasion in tongue squamous cell carcinoma.
Int J Cancer. 2010 Aug 1;127(3):505–512.
[50] Bae E, Sato M, Kim RJ, et al. Definition of smad3
phosphorylation events that affect malignant and meta-
static behaviors in breast cancer cells. Cancer Res. 2014
Nov 1;74(21):6139–6149.
[51] Fu Q, Zhang Q, Lou Y, et al. Primary tumor-derived
exosomes facilitate metastasis by regulating adhesion of
circulating tumor cells via SMAD3 in liver cancer.
Oncogene. 2018; 37:6105–6118.
[52] Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 iden-
tifies cancer exosomes and detects early pancreatic
cancer. Nature. 2015 Jul 9;523(7559):177–182.
[53] Lu H, Niu F, Liu F, et al. Elevated glypican-1 expression is
associated with an unfavorable prognosis in pancreatic duc-
tal adenocarcinoma. CancerMed. 2017 Jun;6(6):1181–1191.
[54] Zhang H, Duan J, Qu Y, et al. Onco-miR-24 regulates
cell growth and apoptosis by targeting BCL2L11 in
gastric cancer. Protein Cell. 2016 Feb;7(2):141–151.
[55] Ji H, Lee JH, Wang Y, et al. EGFR phosphorylates
FAM129B to promote Ras activation. Proc Natl Acad
Sci U S A. 2016 Jan 19;113(3):644–649.
[56] Li H, Zhang Y, Chen SW, et al. Prognostic significance of
Flotillin1 expression in clinically N0 tongue squamous cell
cancer. Int J Clin Exp Pathol. 2014 Feb 15;7(3):996–1003.
12 M. R. DOURADO ET AL.
